Emerging Treatment Options for Peanut Allergy
Allergies,
Год журнала:
2025,
Номер
5(1), С. 5 - 5
Опубликована: Фев. 19, 2025
Peanut
allergy,
a
significant
public
health
issue,
poses
challenges
due
to
its
potential
for
life-threatening
anaphylaxis
and
profound
impact
on
quality
of
life.
Traditional
management
approaches,
including
allergen
avoidance
epinephrine
administration,
are
effective
in
mitigating
acute
symptoms
but
do
not
address
the
underlying
allergy
or
long-term
disease
burden.
Recent
advances
immunotherapy
biologics,
as
well
innovative
technologies
such
gene
editing
microbiome
modulation,
have
introduced
promising
pathways
desensitization
sustained
unresponsiveness.
This
review
provides
comprehensive
exploration
emerging
therapies
peanut
oral,
sublingual,
epicutaneous
immunotherapy,
biologic
agents,
gene-editing
techniques,
novel
drug
therapies.
We
discuss
their
mechanisms,
clinical
efficacy,
associated
challenges,
emphasizing
these
innovations
revolutionize
treatment.
Despite
progress,
barriers
adverse
reactions,
cost,
limited
access
remain.
Addressing
through
further
research
standardization
could
transform
future
management.
Язык: Английский
Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
The Journal of Dermatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 16, 2025
ABSTRACT
The
JAK/STAT
pathway
is
implicated
in
the
pathogenesis
of
cutaneous
T‐cell
lymphoma
(CTCL),
with
early
studies
suggesting
that
JAK
inhibitors
(JAKi)
may
be
used
for
treating
CTCL.
Patients
CTCL
have
other
indications
JAKi
use,
but
data
on
agents
limited
due
to
warnings
against
their
use
malignancy.
We
retrospectively
characterized
experience
our
tertiary
cancer
center
patients
seen
between
years
2011
and
2024.
identified
26
who
received
a
JAKi:
7
prior
diagnosis
(topical
(
n
=
5)
or
oral
2)
itchy
rash
eczema),
6
as
treatment,
13
following
(oral
ruxolitinib
graft
versus
host
disease
(GvHD)
allogeneic
stem
cell
transplant
9),
hemophagocytic
lymphohistiocytosis
3),
topical
alopecia
areata
1)).
Of
six
treated
JAKi,
four
two
ruxolitinib.
One
patient
orally
has
had
complete
response
3
another
diminishing
lesion
size
1
year.
topically
skin‐limited
demonstrated
plaque
thinning.
nine
GvHD,
five
experienced
relapse
median
8
weeks
exposure.
This
study
provides
initial
insights
into
real‐world
Further
studies,
however,
are
required
characterize
any
association
development,
well
safety
context
pre‐existing
Язык: Английский
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(9), С. 2953 - 2953
Опубликована: Апрель 24, 2025
Background:
Atopic
dermatitis
(AD)
is
a
chronic
pruritic
inflammatory
disease
affecting
children
and
adults.
Upadacitinib
abrocitinib
are
selective
Janus
kinase
1
inhibitors
approved
for
the
treatment
of
moderate-to-severe
AD.
Although
their
efficacy
safety
described
in
phase
3
clinical
trials,
real-world
data
limited.
Objectives:
We
aimed
to
evaluate
effectiveness
upadacitinib
real-life
adult
population
with
AD
throughout
an
extended
observation
period.
Methods:
This
retrospective
observational
study
was
conducted
by
analyzing
from
electronic
records
IRCCS
Humanitas
Research
Hospital
January
2023
December
2024.
Patients
were
administered
either
(15
or
30
mg)
(100
200
mg).
Effectiveness
evaluated
using
clinician-reported
scores
(Investigator
Global
Assessment
[IGA]
Eczema
Area
Severity
Index
[EASI])
patient-reported
outcomes
(peak
pruritus
numerical
rating
scale
[PP-NRS])
at
weeks
8,
16,
32
52.
Statistical
significance
set
probability
value
(p-value)
<
0.05.
Adverse
events
also
collected.
Results:
In
total,
129
patients
included
study,
84
them
reached
52
weeks.
At
week
52,
EASI
75,
90,
100
responses
88.9%,
70.8%,
54.2%
upadacitinib,
100%,
91.7%,
75%
abrocitinib.
An
IGA
score
equal
0
achieved
84.7%
treated
100%
those
receiving
A
four-point
reduction
baseline
PP-NRS
reported
86.1%
83.3%
after
one
year
follow-up.
Conclusions:
Our
showed
comparable
even
higher
terms
compared
phase-3
no
new
concerns,
supporting
Язык: Английский
Editor's highlights – November, 2024
International Journal of Dermatology,
Год журнала:
2024,
Номер
63(11), С. 1471 - 1472
Опубликована: Окт. 19, 2024
Abstract
Recent
developments
in
the
understanding
of
pathophysiology
inflammatory
skin
diseases
have
resulted
emergence
new
treatments.
However,
therapies
are
frequently
accompanied
by
side
effects.
In
November
issue
Journal,
we
explore
recent
advances
on
how
Cutibacterium
acnes
phylotypes
involved
biofilm
formation
and
its
significance
therapy
resistance.
The
Janus
kinase
(JAK)
inhibitor‐induced
acneiform
eruptions
also
raise
intriguing
questions
about
complex
relationship
between
JAK
inhibition
acne
pathophysiology.
We
provide
real‐world
data
for
atopic
dermatitis,
hyperkeratotic
hand
foot
generalized
pustular
psoriasis.
Язык: Английский